(via NewsDirect)
Heynen brings a wealth of experience to his role as CEO, with a strong track record in the med-tech industry. He has a history of leadership in technology-driven organizations, ranging from operational start-ups to turnaround situations and high-growth companies.
Heynen's expertise includes managing P&Ls for both North American and international businesses, with multi-site divisions and gross revenues exceeding
In addition to his appointment, Heynen also shared a significant achievement for
Furthermore, NuGen has a distribution agreement in place with Science-Link, aiming to sell approximately 5,000 needle-free injectors in 2024.
Looking to 2024, Heynen outlined NuGen's plans for both geographical market expansion and a strategic shift towards collaborating with pharma companies and healthcare systems. The goal is to broaden the technology's recognition and accessibility, particularly in
The interview showcases NuGen's commitment to revolutionizing medical device technology and improving patient experiences worldwide.
Contact Details
+1 604-688-8158
na-editorial@proactiveinvestors.com
Copyright (c) 2023 TheNewswire - All rights reserved.
Copyright (c) 2023 TheNewswire - All rights reserved., source